NKTR Nektar Therapeutics Stock Quote

NKTR [NASD]

Index	-	P/E	-	EPS (ttm)	-2.48	Insider Own	1.40%	Shs Outstand	179.09M	Perf Week	-6.97%
Market Cap	3.11B	Forward P/E	-	EPS next Y	-2.43	Insider Trans	-5.44%	Shs Float	177.86M	Perf Month	-11.21%
Income	-440.70M	PEG	-	EPS next Q	-0.67	Inst Own	97.80%	Short Float	13.60%	Perf Quarter	-0.33%
Sales	163.30M	P/S	19.07	EPS this Y	-166.60%	Inst Trans	0.10%	Short Ratio	23.29	Perf Half Y	-30.30%
Book/sh	6.54	P/B	2.53	EPS next Y	3.20%	ROA	-25.30%	Target Price	-	Perf Year	-23.93%
Cash/sh	5.08	P/C	3.26	EPS next 5Y	-7.30%	ROE	-34.40%	52W Range	13.63 - 25.06	Perf YTD	-2.59%
Dividend	-	P/FCF	-	EPS past 5Y	-42.70%	ROI	-26.60%	52W High	-33.92%	Beta	1.69
Dividend %	-	Quick Ratio	8.10	Sales past 5Y	-10.60%	Gross Margin	87.10%	52W Low	21.50%	ATR	0.82
Employees	723	Current Ratio	8.30	Sales Q/Q	2.70%	Oper. Margin	-	RSI (14)	40.11	Volatility	3.83% 4.42%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-7.90%	Profit Margin	-	Rel Volume	0.66	Prev Close	16.66
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	Payout	-	Avg Volume	1.04M	Price	16.56
Recom	2.40	SMA20	-8.05%	SMA50	-5.62%	SMA200	-15.47%	Volume	680,557	Change	-0.60%

Jan-06-21

Initiated

Stifel

Hold

$18

Sep-14-20

Initiated

JP Morgan

Neutral

$26

Jun-10-20

Downgrade

CFRA

Hold → Sell

May-12-20

Reiterated

H.C. Wainwright

Neutral

$32 → $26

Apr-22-20

Initiated

The Benchmark Company

Buy

$26

Mar-30-20

Upgrade

Goldman

Sell → Neutral

$18 → $20

Mar-04-20

Initiated

Barclays

Overweight

$30

Feb-03-20

Upgrade

Mizuho

Neutral → Buy

$21 → $35

Oct-24-19

Initiated

Oppenheimer

Perform

$18

Oct-08-19

Downgrade

Goldman

Buy → Sell

$54 → $16

Aug-09-19

Downgrade

Mizuho

Buy → Neutral

$79 → $21

Aug-09-19

Downgrade

JP Morgan

Overweight → Neutral

$62 → $33

Aug-09-19

Downgrade

Jefferies

Buy → Hold

$59 → $23

Mar-15-19

Initiated

SVB Leerink

Mkt Perform

$38

Dec-13-18

Initiated

Goldman

Buy

$62

Jun-11-18

Downgrade

H.C. Wainwright

Buy → Neutral

$54

Jun-04-18

Reiterated

H.C. Wainwright

Buy

$125 → $97

Apr-20-18

Initiated

Seaport Global Securities

Buy

$120

Apr-13-18

Resumed

Piper Jaffray

Overweight

$125

Apr-06-18

Reiterated

Mizuho

Buy

$89 → $103

Jan-06-21 05:00PM	Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference PR Newswire
07:30AM	The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping Benzinga
Jan-05-21 04:20PM	Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development PR Newswire
Dec-22-20 11:03AM	Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options Zacks
08:30AM	Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million PR Newswire
Dec-18-20 08:15PM	Is NKTR A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-16-20 10:45AM	Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers Zacks
Dec-15-20 08:30AM	Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer PR Newswire
Dec-08-20 06:00AM	SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of EQT, ZYNE, NKTR, and FMO; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Dec-07-20 04:00PM	Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting PR Newswire
Dec-05-20 11:32AM	Why Is Nektar (NKTR) Up 3% Since Last Earnings Report? Zacks
Nov-11-20 02:00PM	Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
Nov-10-20 06:47AM	Nektar Therapeutics (NASDAQ:NKTR) Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St.
Nov-09-20 09:04AM	Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat Zacks
Nov-06-20 02:01AM	Nektar Therapeutics (NKTR) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 08:00PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Third Quarter 2020 Financial Results PR Newswire
04:00PM	Nektar Therapeutics to Host Earnings Call ACCESSWIRE
Nov-04-20 10:15AM	New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress PR Newswire +7.61%
Oct-29-20 06:00PM	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress PR Newswire
12:34PM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-20 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets PR Newswire
12:32PM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-27-20 07:30AM	Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19 PR Newswire
Oct-05-20 03:27PM	We Think Nektar Therapeutics (NASDAQ:NKTR) Can Afford To Drive Business Growth Simply Wall St. +6.14%
Sep-28-20 05:24PM	Hedge Funds Are Coming Back To Nektar Therapeutics (NKTR) Insider Monkey
Sep-24-20 06:47PM	Analyst Report: Nektar Therapeutics CoinDesk
Sep-05-20 11:32AM	Nektar (NKTR) Down 12% Since Last Earnings Report: Can It Rebound? Zacks
Aug-12-20 09:42AM	Did Hedge Funds Make The Right Call On Nektar Therapeutics (NKTR) ? Insider Monkey
08:00AM	Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck PR Newswire
Aug-07-20 11:35AM	Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress Zacks
Aug-06-20 07:00PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Second Quarter 2020 Financial Results PR Newswire
Aug-05-20 11:15AM	If You Had Bought Nektar Therapeutics (NASDAQ:NKTR) Stock Five Years Ago, You Could Pocket A 106% Gain Today Simply Wall St.
Jul-30-20 12:33PM	Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline Zacks
Jul-28-20 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets PR Newswire
Jun-23-20 09:46PM	Hedge Funds Arent Impressed By Nektar Therapeutics (NKTR) Insider Monkey
Jun-14-20 09:25PM	Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
Jun-06-20 11:31AM	Why Is Nektar (NKTR) Up 12% Since Last Earnings Report? Zacks
Jun-04-20 05:00PM	Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020) PR Newswire
May-29-20 05:00PM	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020) PR Newswire
May-26-20 11:11AM	7 Stocks Maverick Capital Continues to Buy GuruFocus.com
May-22-20 08:30AM	Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal PR Newswire
May-18-20 08:05AM	Is There An Opportunity With Nektar Therapeutics's (NASDAQ:NKTR) 46% Undervaluation? Simply Wall St.
May-17-20 07:13PM	Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics Investing.com
May-12-20 06:27AM	H.C. Wainwright Sticks to Their Hold Rating for Nektar Therapeutics Investing.com
May-08-20 10:29AM	Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates Zacks
03:57AM	No Surprises in Nektar's Q1; COVID-19 Likely Just a Small Bump in Road for Bempeg Trials Morningstar
03:31AM	Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 05:55PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports First Quarter 2020 Financial Results PR Newswire
Apr-30-20 12:33PM	Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline Zacks
Apr-28-20 05:00PM	Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets PR Newswire
Apr-09-20 06:08PM	Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals
Apr-06-20 06:24AM	Need To Know: Analysts Are Much More Bullish On Nektar Therapeutics (NASDAQ:NKTR) Revenues Simply Wall St. +7.12%
Mar-29-20 10:51PM	Hedge Funds Are Betting On Nektar Therapeutics (NKTR) Insider Monkey
Mar-28-20 11:30AM	Why Is Nektar (NKTR) Down 16.1% Since Last Earnings Report? Zacks
Mar-11-20 09:19PM	Edited Transcript of NKTR earnings conference call or presentation 27-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -8.40%
Mar-01-20 09:15AM	Nektar Therapeutics Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Feb-28-20 06:30PM	Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference PR Newswire
08:15AM	Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up Zacks
04:39AM	Business as Usual for No-Moat Nektar; Bempeg's Phase Three Trials With Bristol to See 2021 Readouts Morningstar
Feb-27-20 05:35PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results PR Newswire
Feb-20-20 12:31PM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-18-20 05:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets PR Newswire
Feb-17-20 10:27AM	Lee Ainslie Buys Crown Holdings, Monster Beverage GuruFocus.com
Feb-10-20 02:56PM	Here's What We Think About Nektar Therapeutics's (NASDAQ:NKTR) CEO Pay Simply Wall St.
09:28AM	Alkermes (ALKS) to Report Q4 Earnings: What's in Store? Zacks
Feb-06-20 05:50PM	Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-03-20 09:12AM	US STOCKS-Wall Street set to open higher after steep selloff Reuters +8.30%
08:00AM	Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications PR Newswire
Jan-29-20 03:46PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-27-20 09:08AM	3 Biotech Stocks Nearing Support Investopedia -6.44%
Jan-24-20 07:02PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR CNW Group
Jan-23-20 11:43AM	Nektar Therapeutics Pullback May Be Short-Lived Schaeffer's Investment Research
Jan-21-20 05:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-16-20 01:37PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-15-20 04:08PM	How An FDA Committee Pulled The Rug Out From This Highflying Biotech Investor's Business Daily -15.99%
10:27AM	Nektar's Pain Drug Gets Adverse Advisory Committee Decision Zacks
10:23AM	Its opioid dissed by FDA advisors, S.F. drugmaker abandons program American City Business Journals
09:17AM	Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 15, 2020: GS, RSX, NKTR, NVAX, ACB Benzinga
08:22AM	The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga
07:30AM	Nektar Stock Plunges 15% as FDA Panel Rejects Opioid Painkiller Barrons.com
04:44AM	Nektar Squeezed as FDA Rejects Opioid Addiction-Fighting Drug TheStreet.com
Jan-14-20 10:47PM	Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol PR Newswire
06:27PM	Nektar stock drops more than 10% as FDA advisers say no to painkiller MarketWatch
10:49AM	'Unlikeable' opioid from Nektar faces FDA pain point American City Business Journals
05:00AM	Top Picks 2020- Nektar Therapeutics NKTR MoneyShow
Jan-13-20 09:14AM	Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration Zacks
Jan-10-20 04:08PM	Why Bristol's Vote Of Confidence Sent This Biotech Stock Rocketing Investor's Business Daily +24.69%
02:32PM	Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders Business Wire
01:34PM	Nektar Therapeutics Options Pop as Stock Soars Schaeffer's Investment Research
08:01AM	Nektar Therapeutics, Bristol-Myers Expand Effort to Develop Treatment for Cancer TheStreet.com
06:59AM	Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab) Business Wire
Jan-07-20 09:00AM	Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire
Dec-24-19 01:09PM	Why A Bidding War For Synthorx Bodes Well For This Biotech Stock Investor's Business Daily
10:10AM	Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On Zacks
Dec-19-19 12:21PM	10 Stocks That Could Be Tax-Loss Buying Opportunities Benzinga
08:59AM	5 Losing Stocks From 2019 to Rebound Next Year Zacks

Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GREER R SCOTT	Director	Jan 05	Option Exercise	13.80	40,000	552,000	225,674	Jan 05 05:09 PM
Myriam Curet	Director	Dec 15	Sale	17.82	1,560	27,799	19,240	Dec 17 06:08 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 23	Sale	16.40	16,380	268,632	250,317	Nov 25 06:09 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 16	Sale	16.93	29,618	501,433	266,697	Nov 18 07:08 PM
Wilson Mark Andrew	SVP & General Counsel	Nov 16	Sale	16.93	1,539	26,055	49,850	Nov 18 07:07 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Nov 16	Sale	16.93	11,976	202,754	159,757	Nov 18 07:05 PM
ROBIN HOWARD W	President & CEO	Nov 16	Sale	16.93	11,975	202,737	352,043	Nov 18 07:04 PM
Labrucherie Gil M	SVP, COO & CFO	Nov 16	Sale	16.93	8,276	140,113	226,973	Nov 18 07:03 PM
Ajer Jeffrey Robert	Director	Sep 28	Sale	17.25	3,250	56,063	25,975	Sep 30 07:03 PM
CHESS ROBERT	Director	Sep 25	Sale	17.75	5,500	97,625	280,573	Sep 25 08:16 PM
Ajer Jeffrey Robert	Director	Sep 21	Sale	19.74	2,250	44,415	20,125	Sep 21 08:58 PM
Labrucherie Gil M	SVP, COO & CFO	Sep 17	Sale	19.96	2,000	39,920	235,249	Sep 21 08:59 PM
CHESS ROBERT	Director	Sep 08	Option Exercise	9.24	8,000	73,920	284,973	Sep 10 08:19 PM
CHESS ROBERT	Director	Sep 08	Sale	18.53	8,000	148,240	276,973	Sep 10 08:19 PM
WHITFIELD ROY A	Director	Sep 04	Option Exercise	9.24	30,000	277,200	228,250	Sep 08 06:18 PM
Labrucherie Gil M	SVP, COO & CFO	Aug 18	Sale	19.68	2,000	39,360	237,249	Aug 19 06:37 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 17	Sale	19.67	26,200	515,354	296,315	Aug 19 06:41 PM
Wilson Mark Andrew	SVP & General Counsel	Aug 17	Sale	19.67	1,529	30,075	51,389	Aug 19 06:40 PM
ROBIN HOWARD W	President & CEO	Aug 17	Sale	19.67	11,885	233,778	364,018	Aug 19 06:38 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Aug 17	Sale	19.67	1,367	26,889	171,733	Aug 19 06:39 PM
Labrucherie Gil M	SVP, COO & CFO	Aug 17	Sale	19.67	6,245	122,839	239,249	Aug 19 06:37 PM
GREER R SCOTT	Director	Jul 09	Option Exercise	9.24	40,000	369,600	191,583	Jul 10 07:06 PM
GREER R SCOTT	Director	Jul 09	Sale	25.00	15,009	375,225	176,574	Jul 10 07:06 PM
CHESS ROBERT	Director	Jul 08	Option Exercise	9.24	8,000	73,920	284,973	Jul 10 07:05 PM
CHESS ROBERT	Director	Jul 08	Sale	24.58	8,000	196,640	276,973	Jul 10 07:05 PM
Labrucherie Gil M	SVP, COO & CFO	May 19	Sale	22.62	2,000	45,240	245,494	May 20 06:29 PM
Zalevsky Jonathan	Chief R&D Officer	May 18	Sale	22.51	4,558	102,601	322,515	May 20 06:33 PM
Wilson Mark Andrew	SVP & General Counsel	May 18	Sale	22.51	1,529	34,418	52,418	May 20 06:32 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	May 18	Sale	22.51	1,367	30,771	172,719	May 20 06:31 PM
Labrucherie Gil M	SVP, COO & CFO	May 18	Sale	22.51	5,727	128,915	247,494	May 20 06:29 PM
ROBIN HOWARD W	President & CEO	May 18	Sale	22.51	8,968	201,870	375,903	May 20 06:30 PM
CHESS ROBERT	Director	Apr 15	Sale	18.38	8,000	147,010	276,973	Apr 17 06:03 PM
CHESS ROBERT	Director	Mar 11	Sale	16.79	8,000	134,316	276,973	Mar 13 06:04 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Feb 18	Sale	22.35	1,394	31,156	174,086	Feb 20 06:39 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 18	Sale	22.35	4,774	106,699	327,073	Feb 20 06:39 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 18	Sale	22.35	5,938	132,714	253,221	Feb 20 06:37 PM
ROBIN HOWARD W	President & CEO	Feb 18	Sale	22.35	8,448	188,813	384,871	Feb 20 06:38 PM
CHESS ROBERT	Director	Feb 12	Sale	23.50	8,000	188,000	276,973	Feb 14 07:00 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Feb 06	Option Exercise	7.21	37,500	270,375	212,980	Feb 07 07:31 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Feb 06	Sale	22.78	37,500	854,250	175,480	Feb 07 07:31 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience